Showing 2211-2220 of 5696 results for "".
- Research: AI Has Perfect Detection Rate for Severe Cases of Retinopathy of Prematurity (ROP)https://modernod.com/news/research-ai-has-perfect-detection-rate-for-severe-cases-of-retinopathy-of-prematurity-rop/2482153/New research from Oregon Health & Science University (OHSU) and collaborators reveal that artificial intelligence technology can accurately and independently detect 100% of severe cases of retinopathy of prematurity (ROP). The research was
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- Sandoz Closes Deal to Acquire Ranibizumab Biosimilar Cimerli from Coherushttps://modernod.com/news/sandoz-closes-deal-to-acquire-ranibizumab-biosimilar-cimerli-from-coherus/2482144/Sandoz has completed the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences. In January, in a move to pay down debt and focus on its oncology business, Coherus BioSciences entered into an agreement to divest its Cimerli (ranibiz
- Amring Pharmaceuticals Changes Name to Nordic Pharma Under New Ownerhttps://modernod.com/news/amring-pharmaceuticals-changes-name-to-nordic-pharma-under-new-owner/2482141/Amring Pharmaceuticals has changed its name to Nordic Pharma, effective today, following the change in ownership of the company from Sever Life Sciences to Nordic Group, a subsidiary of Sever Life Sciences, which occurred on June 1, 2023. The change in the corporate name
- Glaukos' iDose TR Now Commercially Availablehttps://modernod.com/news/glaukos-idose-tr-now-commercially-available/2482139/Glaukos' iDose TR (travoprost intracameral implant 75 mcg), which uses Celanese’s VitalDose EVA (Ethylene Vinyl Acetate) to provide sustained drug release for the treatment of glaucoma, is now commerically available, according to Celanese. The iDo
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat
- PulseSight Therapeutics Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseaseshttps://modernod.com/news/pulsesight-therapeutics-launches-to-advance-non-viral-gene-therapies-for-severe-retinal-diseases/2482134/PulseSight Therapeutics launched today with a portfolio that includes two first-in-class late-stage preclinical drugs for wet and dry age-related macular diseases (AMD), including geographic atrophy (GA). PulseSight’s proprietary non-viral gene therapy ocu
- Nordic Group Appoints Eric Donnenfeld, MD, as Medical Advisory Board Chairhttps://modernod.com/news/nordic-group-appoints-eric-donnenfeld-md-as-medical-advisory-board-chair/2482132/Amring Pharmaceuticals, a subsidiary of Nordic Group, announced that ophthalmologist Eric D. Donnenfeld, MD, will chair its US Medical Advisory Board, which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, O
- Optos Celebrates Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achievedhttps://modernod.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/Optos announced a dual milestone achievement of over 25,000 devices installed worldwide, and the collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states, acccording to a company news release. "This remarkable double milestone reflects the unwavering